Immunotherapy in Lymphoma

Sung-Soo Park

Status

Enrolling

Conditions

Primary Mediastinal Large B-Cell Lymphoma

High Grade B-cell Lymphoma

Relapsed/refractory High Grade B Cell Lymphoma

Diffuse Large B Cell Lymphoma Relapsed

Burkitt Lymphoma

Treatments

Drug: IMiD treatment

Drug: CAR-T Therapy

Drug: Antibody-Drug Conjugate

Drug: Monoclonal antibody

Drug: Proteasome Inhibitor

Drug: Bispecific antibody

Study type

Observational

Funder types

Other

Identifiers

NCT06796517

RS-2023-00216446 (Other Grant/Funding Number)

XC24OIDI0042

Details and patient eligibility

About

The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is:

Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies?

Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes.

Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.

Enrollment

72 estimated patients

Sex

All

Ages

19 to 74 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults aged 19 to 74 years.
Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma
Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma

Exclusion criteria

Patients who have progressed to acute leukemia
Patients who developed solid tumor during treatment
Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)

Trial design

72 participants in 2 patient groups

Advanced immunochemotherapy

Description:

Relapsed/refractory high grade B cell lymphoma patients treated with either chimeric antigen receptor T cell therapy, bispecific antibody, or antibody-drug conjugate

Treatment: